| Literature DB >> 35134690 |
Mohamed S Al Hassan1, Walid El Ansari2, Hamzah El Baba1, Mahir Petkar3, Abdelrahman Abdelaal1.
Abstract
INTRODUCTION: Noninvasive follicular thyroid neoplasm with papillary-like nuclear (NIFTP) is a new entity. No previous study reported prospective cases, outlining using many quantitative and qualitative variables.Entities:
Keywords: Follicular thyroid neoplasm; NIFTP; Nodule; Noninvasive; Papillary thyroid carcinoma; Papillary-like nuclear features
Year: 2022 PMID: 35134690 PMCID: PMC8858746 DOI: 10.1016/j.ijscr.2021.106751
Source DB: PubMed Journal: Int J Surg Case Rep ISSN: 2210-2612
History and treatment characteristics of the sample.
| Characteristic | Value |
|---|---|
| BMI (kg/m2) M ± SD | 29.49 ± 5.74 |
| Comorbidities | |
| No | 11 (73.3) |
| Yes | 4 (26.6) |
| Incidental presentation | |
| No | 13 (86.6) |
| Yes | 2 (13.3) |
| History | |
| Family thyroid cancer | 0 (0) |
| Neck irradiation | 0 (0) |
| Swelling | |
| No | 2 (13.3) |
| Yes | 13 (86.6) |
| Compression symptoms | |
| No | 9 (60) |
| Yes | 6 (40) |
| Duration of symptoms (months) | |
| M ± SD with 1 outlier | 44.1 ± 70.79 |
| M ± SD without outlier | 22.1 ± 17.5 |
| Thyroid state | |
| Euthyroid | 14 (93.3) |
| Hypothyroid | 1 (6.6) |
| TSH (mIU/L) M ± SD | 1.7 ± 1.09 |
| Vitamin D (ng/ml) M ± SD | 25.1 ± 9.38 |
| Treatment n (%) | |
| Type of surgery | |
| Lobectomy | 9 (60) |
| Total thyroidectomy | 6 (40) |
| Date of surgery | |
| 2017 | 1 (6.6) |
| 2018 | 2 (13.3) |
| 2019 | 3 (20) |
| 2020 | 6 (40) |
| 2021 | 3 (20) |
| Post-operative RAI | |
| No | 12 (80) |
| Low dose | 2 (13.3) |
| Unknown dose | 1 (6.6) |
| Completion surgery | |
| No | 13 (86.6) |
| Yes | 2 (13.3) |
| Thyroglobulin (ng/ml) M ± SD | |
| Post-operative | 4.56 ± 4.95 |
| Last recorded | 2.8 ± 3.14 |
All cells represent n (%) except where indicated.
1 patient had epilepsy and migraine, 3 had hypertension.
1 patient discovered during routine women-well screening in Thailand, another discovered during routine medical workup at the Medical Commission in Qatar.
There was one outlier value (240 months), so M ± SD are presented with and without the outlier.
Radioactive iodine dose unknown as the patient sought treatment overseas (Thailand) and dose was delivered there.
Valid percentages reported, numbers might not always add to N = 15 due to missing values; RAI: radioactive iodine.
Thyroid ultrasound characteristics of the sample.
| Characteristic | Value |
|---|---|
| Number of nodules | |
| Single | 4 (28.5) |
| Multiple | 10 (71.4) |
| Size of nodule (cm) M ± SD | |
| Right lobe | 3.44 ± 1.82 |
| Left lobe | 3.44 ± 1.88 |
| Isthmus | 2.11 ± 0.24 |
| Largest nodule | |
| Size (cm) M ± SD | 4.11 ± 1.39 |
| Site | |
| Right | 4 (28.5) |
| Left | 10 (71.4) |
| Suspected abnormality/ies | |
| Site | |
| Right | 5 (35.7) |
| Left | 7 (50) |
| Bilateral | 2 (14.2) |
| Type | |
| Cystic | 1 (7.6) |
| Complex | 8 (61.5) |
| Hypoechoic | 2 (15.3) |
| Isoechoic | 2 (15.3) |
| Vascularity | |
| No | 6 (40) |
| Yes | 9 (60) |
| Type | |
| Intranodular | 4 (40) |
| Perinodular | 4 (40) |
| Both | 2 (20) |
| Calcification | |
| No | 13 (86.6) |
| Micro | 1 (6.6) |
| Macro | 1 (6.6) |
| Lymphadenopathy | |
| Present | |
| No | 4 (26.6) |
| Yes | 11 (73.3) |
| Malignant features | |
| No | 15 (100) |
| Yes | 0 (0) |
| Site | |
| Bilateral non-specific LN | 9 (90) |
| Right submandibular | 1 (10) |
All cells represent n (%) except where indicated; LN: lymph node; valid percentages are presented, numbers might not always add to N = 15 due to missing values.
Histopathology and cytology characteristics of the lesions.
| Characteristic | Value |
|---|---|
| Preoperative | |
| US guide thyroid FNAC | |
| FLUS | 6 (42.8) |
| Follicular neoplasm | 3 (21.4) |
| Colloid nodule | 2 (14.2) |
| Colloid and Hurthle cell changes | 1 (7.1) |
| Atypical | 1 (7.1) |
| Inadequate | 1 (7.1) |
| Bethesda category | |
| I | 1 (7.1) |
| II | 3 (21.4) |
| III | 7 (50) |
| IV | 3 (21.4) |
| V | 0 (0) |
| VI | 0 (0) |
| Histopathology | |
| NIFTP | 13 (86.6) |
| NIFTP+PMC | 2 (13.3) |
| Site of pathology | |
| Right | 7 (46.6) |
| Left | 7 (46.6) |
| Bilateral | 1 (6.6) |
| Number of foci | |
| Unifocal | 13 (86.6) |
| Multifocal | 2 (13.3) |
| Size of foci (cm) | 2.1 ± 1.75 |
All cells represent n (%) except where indicated; US: ultrasound; FNAC: fine needle aspiration and cytology; FLUS: follicular lesion of undetermined significance.
Mean size of foci = sum of all unifocal lesions and the largest foci in the multifocal lesions divided by the number of lesions; valid percentages are presented; numbers might not always add to N = 15 due to missing values.
Fig. 1A) Low power view showing a well circumscribed NIFTP in the right, with normal thyroid parenchyma on the left (H and E × 2); B) the NIFTP shows features similar to papillary thyroid carcinoma, including irregular nuclear outlines, nuclear irregularities and prominent grooves (black arrowhead) (H and E × 60); C) occasional foci of pseudoinclusions are also noted (arrows) (H and E × 60).
Fig. 2Ultrasound of left thyroid lobe showing: A) well-defined solid nodule (5.18 × 2.78 cm) at the lower part; and, B) well-defined solid nodule with mild internal vascularity, but no calcifications or cystic changes.
Fig. 3Ultrasound of left thyroid lobe showing: A) complex nodule (4.2 × 1.8 × 2.2 cm) occupying almost the entire lobe, containing cyst with thick irregular wall and clear content; and, B) complex nodule with peripheral vascularity, and no obvious internal vascularity.
Fig. 4Ultrasound of right thyroid lobe with: A) well-defined solid hypoechoic nodule at the mid part (1.66 × 0.92 cm), with no calcifications or cystic changes; and B) well-defined complex nodule at the lower part (2.53 × 1.06 cm), with calcifications.
Fig. 5Ultrasound of left thyroid lobe with: A) well-defined complex hypoechoic nodule at upper part (2.91 × 2.24 cm); and B) well-defined complex hypoechoic nodule with internal vascularity.
Detailed profiles of 15 prospective cases of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
| Case/year | Age/sex | Nat | Symp | BMI | TS | LN | SM of Ln | Site by US | FNAC | BC | Site of higher BC | S | FD by HP | Site by HP | PO CTT | PO TG | Final TG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1/2018 | 41/M | Eg | N | 28.73 | E | Y | N | L | FLUS | III | L | LO | NIFTP | L | N | 10.5 | 4.9 |
| 2/2020 | 33/F | Eg | Y | 26.11 | E | N | NAp | L | FLUS | III | L | T | NIFTP+PMC | Bi | LRAI | 0.1 | 0.1 |
| 3/2019 | 52/F | Q | Y | 30.36 | H | Y | N | Bi | FN + HC & C | IV | R | T | NIFTP | L | N | NA | NA |
| 4/2017 | 44/F | Q | Y | 29.05 | E | N | NAp | R | FLUS | III | R | T | NIFTP | R | RAI | 10.7 | 5.8 |
| 5/2018 | 31/F | F | Y | NA | E | Y | N | L | FLUS | III | L | LO | NIFTP | L | T | NA | NA |
| 6/2019 | 33/F | Eg | Y | 45.91 | E | Y | N | Bi | C + HC | IV | L | LO | NIFTP | L | N | 7.7 | NA |
| 7/2019 | 34/M | Tn | Y | 28.32 | E | Y | N | L | C | II | L | LO | NIFTP | L | N | 5.7 | NA |
| 8/2020 | 38/F | Q | Y | 24.61 | E | Y | N | R | FN | IV | R | LO | NIFTP | R | N | NA | NA |
| 9/2020 | 36/F | Eg | N | NA | E | Y | N | L | AC | III | L | LO | NIFTP | L | N | NA | NA |
| 10/2020 | 57/F | Q | Y | 33.21 | E | Y | N | R | FLUS | III | R | T | NIFTP | R | N | 0.1 | 0.1 |
| 11/2020 | 42/M | P | Y | 27.04 | E | Y | N | R | Inadequate | I | R | LO | NIFTP+PMC | R | LRAI+T | 1.4 | 0.1 |
| 12/2020 | 27/M | I | Y | 27.34 | E | Y | N | R | FLUS | III | R | LO | NIFTP | R | N | NA | NA |
| 13/2021 | 60/F | Q | Y | 28.6 | E | N | NAp | — | — | — | — | T | NIFTP | R | N | 0.3 | 0.2 |
| 14/2021 | 52/F | F | Y | 29.15 | E | Y | N | L | C | II | Bi | T | NIFTP | R | N | 0.5 | NA |
| 15/2021 | 43/F | F | Y | 24.97 | E | N | N | L | FN | IV | L | LO | NIFTP | L | N | NA | NA |
AC: atypical cells; BC: Bethesda category; Bi: bilateral; C: colloid; CTT: completion treatment; E: euthyroid; Eg: Egyptian; F: Filipino; FLUS: follicular lesion of undetermined significance; FNAC: fine needle aspiration and cytology; FD: final diagnosis; FN: follicular neoplasm; HC: Hürthle cell type; H: hypothyroid; I: Indian; Ln: lymph node; LN: Lymphadenopathy; LO: lobectomy; LRAI: Low dose radioactive iodine; L: left; N: no; NA: data not available; NAp: not applicable; Nat: nationality; NIFTP: noninvasive follicular thyroid neoplasm with papillary-like nuclear features; NS: non-specific; P: Pakistani; PO CTT: post-operative completion treatment; PO TG: post-operative thyroglobulin; PMC: papillary microcarcinoma; Q: Qatari; R: right; RAI: Radioactive iodine, dose unknown as it was delivered overseas (Thailand); S: surgery; SM: suspected malignancy; Symp: symptomatic; T: total thyroidectomy; Tn: Tunisian; TS: thyroid status; US: ultrasound; Y: yes; -ve: negative; +ve: positive; —: not done. The Bethesda System for Reporting Thyroid Cytopathology (BSRTC): 6 categories for thyroid cytology reporting [I-nondiagnostic, II-benign, III-atypia of undetermined significance (AUS)/follicular lesion of undetermined significance (FLUS), IV-follicular neoplasm/suspicious for follicular neoplasm (SFN), V-suspicious for malignancy, and VI-malignant].
Body mass index in kg/m2.
Patient had ultrasound showing left thyroid lobe nodule with calcifications for which the radiologist recommended FNA from left thyroid lobe, however US guided FNA was done from the 2 lobes.
Cases with discrepancies detailed in the discussion section.
Three cases underwent surgery despite their low BSRTC category. Case 11 (BSRTC category I) had FNA twice and both cytology samples were inadequate, however MDT recommended lobectomy as patient was symptomatic, Cases 7 and 14 (both BSRTC category II) had lobectomy and total thyroidectomy respectively as both patients were symptomatic and FNAC showed colloid nodule.
Case 13 FNAC was not done, surgery was done as patient was symptomatic and US showed MNG.